The IEEE 2030 Technology Megatrends Report projects that gene editing and therapy will become routine treatments for a broad range of illnesses within the next decade. The forecast, released in early 2024, attributes this shift to rapid progress in artificial intelligence, which is accelerating drug discovery and precision medicine.
The report highlights how AI can sift through vast genomic data, identify disease‑causing mutations, and design targeted therapies faster than traditional methods. By 2028, hospitals worldwide are expected to integrate these tools, offering personalized cures for conditions such as inherited heart defects, certain cancers, and rare metabolic disorders.
Artificial intelligence is now capable of predicting how specific genetic edits will interact with a patient’s unique biology. Researchers are using machine learning models to simulate outcomes before clinical trials, reducing both time and cost. In one study cited by IEEE, an AI platform proposed a CRISPR‑based fix for a rare muscular dystrophy in under two weeks, a process that previously took months. This rapid prototyping is expected to bring more gene therapies to market, making them accessible to patients who previously had limited options.
The question of whether gene editing will replace conventional drugs depends on regulatory approvals and public trust. Regulatory bodies are already adapting guidelines to accommodate AI‑generated therapeutic designs. Public acceptance hinges on transparency about risks and long‑term monitoring. If these hurdles are overcome, hospitals could routinely offer gene‑edited treatments, reshaping the healthcare landscape.
The broader implications include a potential decline in chronic medication usage and a shift toward preventive care. Economically, the cost of gene therapies may rise initially, but long‑term savings could result from reduced hospital stays and fewer complications. Societally, the promise of curing genetic diseases may spark ethical debates about access, equity, and the definition of „normal” human biology.
What diseases are likely to see gene therapy first? Early adopters include inherited heart conditions, certain cancers, and rare metabolic disorders where specific gene mutations are well understood.
How does AI improve safety in gene editing? AI models predict off‑target effects and immune responses before clinical trials, allowing researchers to refine designs and minimize adverse outcomes.
Will gene therapy be affordable for all? Initial costs are high, but as production scales and AI reduces development time, prices are expected to drop, potentially making treatments more widely available.